폐경후 증후군 환자에서 Estradiol Patch 치료의 임상 효과 : 제 1 보

김성완,장윤석,윤병구,조보연,이진용,이홍규,고창순,민헌기,박용수,이동수,김정구,김성연 대한내분비학회 1990 Endocrinology and metabolism Vol.5 No.2

We evaluated clinical efficacy and acceptability of transdermal estradiol patch treatment (beta estro, 1 mg/patch) in 30 patients with hot flushes and/or postmenopausal syndrome. 26 of 29 patients with hot flushes and 1 patient with postmenopausal syndrome were found to experience the improvement of symptoms. 1 of 3 patients who did not experience clinical improvement with patch treatment experienced the improvement of urinary symptoms and headaches. Among 3 of 26 patients who experienced improvement in hot flushes, 1 patient sufferes aggravation of headache and 2 patients complained generalized myalgia and dysphoria during treatment. 1 patient whose symptoms had not improved was the one who had the history of skin allergy against plasters and suffered the severe irritation symptoms at the sites of patch application and stopped the patch trement at 10th day of trial. The other 29 did not complain any side effects other than mild skin hyperemia at the site of plaster contact. 25 patients agreed that estradoil (beta estro 1 mg/patch) treatment for two weeks were "effective: in the amenlioration of their postmenpausal symptoms. The above findings showed that the trasdermal estradiol patch treatment improved severity scroes of hot flushes and symptoms of postmenopausal syndrome. Any significant side effect to stop the treament was not observed for 2 weeks of treament and the ratio (83%) of the subjective "effective" group with transdermal estradiol therapy suggessted that this modality might be an alternative of estrogen delivery for longterm treatment in patients with hot flushes and postmenopausal syndromes. (J Kor Soc Endocrinol 5: 131~140, 1990)

러시아어 슬랭의 주제별 그룹에 대한 연구

김성완 한국노어노문학회 2007 한국노어노문학회 학술대회 발표집 Vol.2007 No.9

The innate immune response transcription factor Bombyx mori Relish1 induces high-level antimicrobial peptides in silkworm

김성완,김성열,구태원,최광호 한국잠사학회 2018 International Journal of Industrial Entomology Vol.37 No.2

To artificially enhance antimicrobial peptide expression in Bombyx mori, we constructed genetically engineered silkworms overexpressing Rel family transcription factor. The truncated BmRelish1 (BmRelish1t) gene contained a Rel homolog domain (RHD), nuclear localization signal (NLS), acidic and hydrophobic amino acid (AHAA)-rich region, and death domain (DD), but no ankyrin-repeat (ANK) domain. The BmRelish1t gene was controlled by B. mori cytoplasmic actin 3 promoter in the PiggyBac transposon vector. Chromosome analysis of G1 generations of a transgenic silkworm with EGFP expression confirmed stable insertion of BmRelish1t. BmRelish1t gene overexpression in transgenic silkworms resulted in higher mRNA expression levels of B. mori antimicrobial peptides such as lebocin(~20.5-fold), moricin(~8.7-fold), and nuecin(~17.4-fold) than those in normal silkworms.

특집 - 불과 건축 : 건물의 외단열과 내단열 ( Inside and Outside Insulation for Building )

김성완 대한건축학회 1992 建築 Vol.36 No.6

단열재는 일반적으로 건물의 외피(외벽, 지붕, 바닥 등)에 설치하게 되며, 설치위치에 따라 외단열, 중단열, 내단열로 구분하고 있다. 실내외의 온도가 일정한 상태로 유지될 때의 정상열류하에서는 단열재 위치에 관계없이 단열성능은 동일하다고 볼 수 있으나, 내외온도가 수시로 변화하는 실제상황에서는 구조체의 축열성능 등에 의해 단열재위치에 따라 효과가 다르게 나타난다. 이 글에서는 단열재의 설치위치에 따른 건물성능의 차이점을 비교하여 건물구조 및 목적에 적합한 단열방법에 대해 검토한다.

철광석의 소결성에 미치는 석회소성 슬러지 첨가의 영향

김성완,김태동,김종련,김종래 대한금속재료학회(대한금속학회) 1998 대한금속·재료학회지 Vol.36 No.10

In order to utilize the limestone sludge of limestone calcination plant as a by-product, present study had been performed to estimate the usability of limestone sludge as a raw material of sinter mixture in iron ore sintering process and the influence of addition of limestone slurry and dried limestone sludge on the sintering properties. The results of sintering pot tests showed that limestone sludges might be used in iron ore sintering process in the phase of slurry and dried powder without the deterioration of sinter quality. The optimum density of limestone slurry and ratio of sludge to sinter mixture were 20% and 1.2%, respectively. In the respect of sinter quality, strength(TI) and reduction index(RI) was decreased with the increase of limestone sludge containing dolomite particles due to the decrease of calcium ferrite and the increase of low reducible magnetite of sinter.

기술자료 : 하드코팅계표면처리 및 표면개질 (1) -하드코팅기술의 특성

김성완 한국열처리공학회 2013 熱處理工學會誌 Vol.26 No.6

폐경후 증후군 환자에서 Estradiol Patch치료의 약동학 및 적용 가능성

김성완,장윤석,윤병구,조보연,이진용,이홍규,고창순,민헌기,이문규,박용수,이동수,김정구,김성연 대한내분비학회 1989 Endocrinology and metabolism Vol.4 No.3

Postmenopausal syndrome is due to estrogen deficiency. Oral estrogen therapy results in a relatively small increase in serum levels of estraodiol and a large increase in serum concentrations of estrone, which requests large amount of estrogen and might provoke endometrial hyperplasia and carcinoma in addition to systemic side effects. Transdermal estrogen therapy is more favorable for the delivery of estradiol to maintain serum concentration without those side effects and risks of oral therapy. We evaluated pharmacokinetics and acceptability of estrogen patch therapy ( -ESTRO, estradiol 1 mg/patch) in 13 postmenopausal healthy volunteers and 35 patients with vasomotor symptoms and postmenopausal syndrome. The observed results were as follows: 1) In 13 healthy volunteers, serum estradiol concentration (mean±SD) rose by 2 hours after patch application and reached the concentration of 126.4±99.0 pg/ml at 6 hours, and maintained at the level of 41.1±33.7 and 42.8±14.9 pg/ml after 24 hours and 48 hours respectiv 2) In 35 patients, serum estradiol concentration (mean±SD) rose by 2 hours after patch application and reached the concentration of 123.0±100.0 pg/ml at 6 hours, and remained at 75.8±57.5 pg/ml after 24 hours, 75.7±57.5 pg/ml after 48 hours, 84.0±26.2 pg/ml after I week, and 40.4±18.9 pg/ml after 2 week. 3) Side effects observed with estradiol patch therapy were mainly mild symptoms of local skin irritation such as rash and itching. In some cases headache, nausea, vomiting, breast welling and pain, and vaginal spotting were rarely observed. In two cases, estradiol patch therapy was discontinued due to urticaria or systemic side effects of headache and vomiting due to too much estrogen absorbed, which disappeared within several hours after patch removal. These data suggest that estradiol patch therapy in patients with postmenopausal syndrome could maintain therapeutic level of serum estradiol with minor tolerable side effects. (J. Kor Soc Endocrinol 4:203~208, 1989)

현대 러시아어에 있어서의 언어 민주화

김성완 한국노어노문학회 2016 한국노어노문학회 학술대회 발표집 Vol.2016 No.4

유방암 환자에서 항우울제의 사용

김성완,김선영,김재민,박민호,윤정한,신일선,윤진상 대한정신약물학회 2009 대한정신약물학회지 Vol.20 No.2

Depression is common among patients with breast cancer and has been found to influence quality of life and disease course as well as to increase fatigue, pain, and insomnia. Therefore, it is very important to treat depression among breast cancer patients with antidepressants in order to improve clinical outcomes. However, inconsistent results about the consequences of antidepressant use in patients with breast cancer have been reported. This article reviews and discusses the following issues:epidemiologic data about depression in patients with breast cancer; debates about the association between antidepressant use and breast cancer risk;pharmacological interactions of antidepressants and medications for breast cancer, including tamoxifen and opioids;data from clinical trials addressing the effect of antidepressants on depressive symptoms in patients with breast cancer; and data from clinical trials addressing the effect of antidepressants on cancer-related symptoms, including hot flashes, post-mastectomy pain syndrome, nausea, pruritus, fatigue, and sexual dysfunction. This review article contributes to a comprehensive understanding of the use of antidepressants in patients with breast cancer 우울증은 유방암 환자의 삶의 질과 암의 임상경과에 중대한 영향을 미친다. 때문에 적절한 항우울제의 사용은 암 환자의 삶의 질과 기능을 개선하고 임상경과에 긍정적 영향을 미칠 수 있다. 하지만 유방암 환자의 우울증치료는 일반 우울증 치료와는 다른 특성을 지니는데, 이는 에스트로겐, 프로락틴 등의 호르몬이 유방암의 발생 및 항우울제의 효능과 밀접한 관련성을 갖고 있기 때문이다. 특히 항우울제와 유방암 치료제인 tamoxifen 간의 CYP 2D6 상호작용은 유방암의 예후에 영향을 미칠 수 있으므로 주의해야 한다. 항우울제는 유방암 환자의 우울증 개선에 효과적인 것은 물론이고 유방암 및 유방암치료 관련 증상인 안면홍조, 피로감, 매스꺼움, 가려움, 통증 등에도 효과가 보고되어 유방암 환자에게 여러모로 유용하게 사용될 수 있다. 따라서 항우울제의 효능은 물론이고 각 약물의 약역학적, 약동학적 특성과 부작용, 우울증의 임상양상, 유방암의 임상경과를 모두 고려하여 적절한 항우울제를 선택하는 것이 필요하다.

원발성 폐암의 외과적 치료

김성완,구본원,이응배,전상훈,장봉현,이종태,김규태,강덕식 대한흉부심장혈관외과학회 1998 Journal of Chest Surgery (J Chest Surg) Vol.31 No.2

최근 원발성 폐암의 유병률이 점점 증가하고 있으며, 비소세포폐암의 완치 목적의 치료로 외과적 폐절제술이 가장 좋은 방법으로 알려져있다. 저자들은 1992년 1월부터 1995년 7월까지 경북대학교병원 흉부외과에서 원발성 비소세포폐암으로 폐 절제술을 받은 환자중 100례의 임상기록을 분석하여 다음과 같은 결과를 얻었다. 남자가 86례, 여자가 14례로 남녀비는 6 : 1이었고, 60대가 43%로 환자의 대부분을 차지하였고 최소 34세 및 최고 81세였다. 수술수기는 단엽절제술 55례(55%), 전폐절제술 22(22%), 쌍엽절제술 15례(15%), 구역절제술 2례(2%) 및 기관지성형술이 필요했던 수상엽절제술, 수상전폐절제술 및 쐐기전폐절제술이 각각 4례, 1례 및 1례였다. 수술후 조직학적 분류는 편평상피세포암 67례(67%), 선암 26례(26%), 거대세포암 6례(6%) 및 선평편상피세포암 1례(1%)였다. 종격림프절로 전이가 있었던 예는 총 18례(18%)였으며, 편평상피세포암이 8/67(11.9%)례, 선암이 9/26(34.6%)례, 거대세포암이 1/6(16.7%)례였다. 술후 병리학적 병기는 1병기 45례(45%), 2병기 13례(13%), 3a병기 36례(36%), 3b병기 5례(5%) 및 4병기 1례(1%)였다. 전체 환자에서의 12개월, 24개월, 36개월 및 43개월의 생명표법에의한 생존률은 각각 77.5%, 56.1%, 43.7% 및 43.7%였으며, 병기별 43개월의 생존률은 1병기에서 81.3%, 2병기에서 20.8%, 3a병기에서 27.9%, 3b병기에서 25.0%였다. 수술후 병원사망은 패혈증 2례, 호흡부전 1례 및 급성 심경색에 의한 급사가 1례로 총 4례(4%)였다. 원발성폐암의 절제술후 생존률을 향상시키기 위해서는 조기 발견 및 수술적응 환자의 적극적인 수술이 필요한 것으로 판단되었다.Hg로 감소하였고 폐동맥압의 평균은 수술전에 11.4$\pm$5.68 mmHg에서 25.94$\pm$11.53, 29.67$\pm$9.31 mmHg로 증가 하였으나 모두 통계적 의의는 없었다(p>0.05). 양측 폐이식수술에서인 폐동정맥문합부위의 파열, 협착, 뒤틀림 등의 수술수기상의 문제점을 예방하면서 우측폐를 먼저 이식하면서, 폐수술시야를 충분히 확보하고, 재관류손상을 방지하는 경우 cystic fibrosis, pulmonary hypertention, emphysema와 같은 심한 호흡부전증 환자의 치료방법으로 적합하리라 사료된다.에서 선택수술 (elective coronary artery bypass graft)에 비하여 특별한 위험 요소의 증가 관상 동맥 우회술을 적용하여 좋은 결과를 얻을 수 있었으며 이들에 대한 장기 추적이 릴요할 된다.착군에 비하여 의미있게 작았는데 이는 아마도수술 당시 협 착 부위의 완전제거가 이루어지지 않은 것이 원인이라고 사료되었다. 본 분석에서는 어린 연령(3개월 이하), 3개월이하에 시행한 쇄골하동맥편 교약성형술이 의미있는 재협착의 위험요소로 밝혀졌다. 결론 적으로 저자등은 본연구를 통하여 대동맥협부지수, 횡대동맥 지수 등이 개개 대동맥교약 환아의 해부학 적, 임상적 특징을 파악하는데 도움이 되는 도구라는 사실을 발견하였고 아울러 교약의 해부학적 특성, 동반 심기 형, 연령, 수술방법 등이 수술사망 및 재협착에 영향한다는 사실을 입증하였다.t was resulted from increase of weight of single cocoon. "Manta"2.5ppm produced 22.2kg of cocoon. It is equal to 9% increase in index, as compared to that of control. In case Primary lung cancer has recently increased progressively in its incidence in Korea. It is clearly evident that surgical resection offers the best offortunity for cure of non-small cell carcinoma. This study was designed to analyse the clinical data of 100 primary non-small cell carcinoma patients who underwent lung resection surgery from January 1992 to July 1995 at the department of Thoracic and Cardiovascular Sugery, Kyungpook National University Hospital. There were 86 males and 14 females(6:1). In the age distribution, the peak incidence was recorded in the seventh decade(43%). The methods of tissue diagnosis were bronchoscopic biopsy in 53 patients(50.5%), percutaneous needle aspiration in 17 patients(16.2%), transbronchial lung biopsy in 11 patients(10.5%), mediastinoscopic biopsy in 2 patients (1.9%), sputum cytology in 2 patients(1.9%), and thoracotomy in 20 patients(19.0%). Fifty-five lobectomies, 22 pneumonectomies, 15 bilobectomies, 2 segmentectomies, 4 sleeve lobectomies, a sleeve pneumonectomy, and a wedge pneumonectomy were performed. Operative mortality occured in 4 cases(sepsis in 2 cases, respiratory failure in 1 case, and acute myocardiac infarction in 1 case). The histologic types of tumor were 67 squamous cell carcinomas, 26 adenocarcinomas, 6 large cell carcinomas, and an adenosquamous cell carcinoma. Eighteen patients with N2 mediastinal lymph node metastases had 8 squamous cell carcinomas(11.9%), 9 adenocarcinomas(34.6%), and a large cell carcinoma(16.7%). The primary tumors in these patients were in the right upper lobe in 4 patients, the right middle and lower lobe in 9 patients, the left upper lobe in 3 patients, and the left lower lobe in 2 patients. With regard to pathologic stages, 45 patients had stage I disease; 13 patients, stage II; 36 patients, stage IIIa; 5 patients, stage IIIb; and 1 patient, stage IV. The overall actuarial survival rate was 77.5% at 12 months, 56.1% at 24 months and 43.7% at 43 months. The actuarial survival rates at 43 months were 81.3% in Stage I, 20.8% in Stage II, 27.9% in Stage IIIa, 25.0% in Stage IIIb and 33.3% in Stage IV. These facts suggest that early detection and surgical resection are recommended for favorable postoperative survival in non-small cell lung cancer.